Department of Pathology, University of Pittsburgh, Pittsburgh, 15231, PA, USA.
University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, 15231, USA.
Breast Cancer Res. 2018 Nov 20;20(1):144. doi: 10.1186/s13058-018-1066-z.
Epidemiologic studies have, variably, shown the concomitant use of statin drugs to be beneficial to cancer outcomes. Statin drugs have been FDA approved for three decades for the treatment of high cholesterol and atherosclerotic coronary artery disease and are widely used. This has engendered studies as to their influence on concomitant diseases, including cancers. In this context, statin use has been correlated, variably, with a decrease in deaths from breast cancer. However, there is no extant model for this effect, and the extent of efficacy is open to question.The overarching goal of this article is to communicate to the reader of the potential of statins to reduce breast cancer progression and mortality. This is the use as a secondary prevention measure, and not as a therapy to directly counter active cancer. First, salient aspects of statin pharmacology, as relates to cardiovascular disease, will be discussed. Second, the basic and clinical research studies that investigate statin usage in breast cancer will be presented. Additionally, statin effects in other cancer types will be included for context. Finally, proposals for future basic and clinical research studies to determine the role of statins in breast cancer management will be presented.
流行病学研究表明，同时使用他汀类药物对癌症结局有益。他汀类药物已被 FDA 批准用于治疗高胆固醇和动脉粥样硬化性冠心病三十年，并且被广泛使用。这引发了关于它们对包括癌症在内的伴随疾病影响的研究。在这种情况下，他汀类药物的使用与乳腺癌死亡率的降低有关，但目前尚不存在这种效果的模型，其疗效程度也存在疑问。本文的总体目标是向读者传达他汀类药物降低乳腺癌进展和死亡率的潜力。这是作为二级预防措施的使用，而不是直接对抗活动性癌症的治疗方法。首先，将讨论与心血管疾病相关的他汀类药物药理学的重要方面。其次，将介绍研究他汀类药物在乳腺癌中使用的基础和临床研究。此外，还将包括其他癌症类型的他汀类药物的影响以作参考。最后，将提出未来的基础和临床研究提案，以确定他汀类药物在乳腺癌管理中的作用。
